Effects of probucol on endothelial damage by 5-fluorouracil

Acta Oncologica

Volumn 42, Issue 4, 2003, Pages 304-308

  Kinhult, Sara ^a   Albertsson, Maria ^a   Eskilsson, Jan ^a   Cwikiel, Magdalena ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANTS; CARDIOLOGY; PATHOLOGY; SCANNING ELECTRON MICROSCOPY; TUMORS;

THROMBOGENIC EFFECTS;

ONCOLOGY;

ANTILIPEMIC AGENT; ANTIOXIDANT; FLUOROURACIL; PROBUCOL; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELL DAMAGE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; ENDOTHELIUM CELL; HUMAN; INTIMA; LOW DRUG DOSE; MALE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RABBIT; SCANNING ELECTRON MICROSCOPY; THROMBOGENICITY; TOXICITY; VASCULAR ENDOTHELIUM;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIMETABOLITES, ANTINEOPLASTIC; ARTERIES; ENDOTHELIUM, VASCULAR; FLUOROURACIL; INJECTIONS, INTRAPERITONEAL; MALE; MICROSCOPY, ELECTRON, SCANNING; PROBUCOL; RABBITS; THROMBOSIS;

EID: 0037825850     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860310004409     Document Type: Article

References (21)

1. Robben FR, Pippas A, Moore J. The syndrome of 5-fluorouracil cardiotoxicity. Cancer 1993; 71: 493-509.
2. Labianca R, Berreta G, Clerici M, Fraschini P, Luporini G. Cardiac toxicity of 5-fluorouracil: a study on 1 083 patients. Tumori 1982; 68: 505-10.
3. Becker K, Erckenbrech F, Häusing D, Frieling T. Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs 1999; 57: 475-84.
4. Cwikiel M, Eskilsson J, Wieslander JB, Stjernqvist U, Albertsson M. The appearance of endothelium in small arteries after the treatment with 5-fluorouracil. An electron microscopic study of its late effects in rabbits. Scanning Microsc 1996; 10: 805-20.
5. Cwikiel M, Albertsson M, Eskilsson J, Stavenov L. The infuence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in culture. Ann Oncol 1996; 7: 731-7.
6. Kehrer JP. Free radicals as mediators of tissue injury and disease. Crit Rev Toxicol 1993; 23: 21-48.
7. Buckley M, Goa KL, Price AH, Brogden RN. Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia. Drugs 1989; 37: 761-800.
8. Siveski-Iliscovic N, Hill M, Chow DA, Singal PK. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 1995; 91: 10-5.
9. Li T, Danelisen I, Belló-Klein A, Singal PK. Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats. Cardiovasc Res 2000; 46: 523-30.
10. Zapolska-Downar D, Zapolski-Downar A, Markiewski M, Ciechanowicz A, Kaczmarczyk M, Naruszewicz M. Selective inhibition by probucol of vascular cell adhesion molecule-1 (VCAM-1) expression in human vascular endothelial cells. Atherosclerosis 2001; 155: 123-30.
11. Jiang JL, Li NS, Li YJ, Deng HW. Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level. Br J Pharmacol 2002; 135: 1175-82.
12. Witztum JL, Steinberg D. The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends Cardiovasc Med 2001; 11: 93-102.
13. Wieslander JB, Stjernqvist U. The influence of non-ionic contrast media on the endothelium of small arteries. Acta Radiol Suppl 1987; 370: 73-7.
14. Durak I, Karaayvaz M, Kavutcu M, et al. Reduced antioxidant defense capacity in myocardial tissue from guinea pigs treated with 5-fluorouracil. J Toxicol Environ Health 2000; 59: 585-9.
15. Jung ID, Yang SY, Park CG, et al. 5-Fluorouracil inhibits nitric oxide production through the inactivation of I kappa B kinase in stomach cancer cells. Biochem Pharmacol 2002; 64: 1439-45.
16. Matthews NE, Adams MA, Maxwell LR, Gofton TE, Graham CH. Nitic oxide-mediated regulation of chemosensitivity in cancer cells. J Natl Cancer Inst 2001; 93: 1879-85.
17. Oshima T, Imada T, Nagashima Y, et al. Role of nitric oxide in human gastric cancer cells treated with 5-fluorouracil. Oncol Rep 2001; 8: 847-9.
18. Stathopoulos GP, Malamos NA, Dontas I, Deliconstantinos G, Perrea-Kotsareli D, Karayannacos PE. Inhibition of adriamycin cardiotoxicity by 5-fluorouracil: a potential free oxygen radical scavenger. Anticancer Res 1998; 18: 4387-92.
19. Jin Y, Heck DE, DeGeorge F, Tian Y, Laskin JD. 5-Fluorouracil suppresses nitric oxide biosynthesis in colon carcinoma cells. Cancer Res 1996; 56: 1978-82.
20. Ruef J, Peter K, Nordt TK, Runge MS, Kübler W, Bode C. Oxidative stress and atherosclerosis: its relationship to growth factors, thrombus formation and therapeutic approaches. Thromb Haemost 1999; 82(Suppl): 32-7.
21. Reinoehl J, Frankovich D, Machado C, et al. Probucol-associated tachyarrhythmic events and QT prolongation: importance of gender. Am Heart J 1996; 131: 1184-91.